Don't Retrain, Just Reuse: Recovering Dual-Target Molecules from Single-Target Diffusion Models
arXiv:2605.25681v1 Announce Type: new Abstract: Designing a single molecule that modulates two targets is a promising strategy for polypharmacology, but it remains substantially harder than standard single-target generation because one candidate must satisfy two binding requirements while preserving drug-likeness and synthesizability. Existing dual-target generative methods typically introduce dual-target capability by either retraining the generator or intervening in the diffusion process during sampling. The former can be costly and difficult to stabilize when dual-target supervision is spar
This research is emerging now due to advances in generative AI models, particularly diffusion models, and the increasing demand for more efficient drug discovery and design processes.
Improving the efficiency of multi-target drug design significantly reduces R&D costs and accelerates the development of complex therapeutics, addressing diseases with multifactorial pathologies.
The ability to generate dual-target molecules more efficiently, without retraining expensive models, streamlines drug discovery workflows and lowers barriers to entry for novel drug development.
- · Pharmaceutical R&D
- · Biotech startups
- · AI in drug discovery
- · Patients with complex diseases
- · Traditional drug screening methods
- · Companies relying on single-target approaches
More rapid identification and development of multi-target drug candidates.
A shift towards polypharmacology as a preferred strategy for certain disease categories, leading to more effective and potentially safer treatments.
Enhanced global health outcomes and a redistribution of innovation leadership in drug development as smaller, agile AI-driven entities gain leverage.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.LG